Medical Cannabis Consulting for the Pharmaceutical Industry
Operating in the medicinal cannabidiol market demands a high level of technical specialization, multi-jurisdictional regulatory expertise, and genuine execution capacity.
The pharmaceutical consultancy ELS Group acts as a strategic partner for companies wishing to develop, regulate, produce, and market medicinal cannabis-based products in a safe, sustainable manner, and in compliance with applicable legal requirements.
We support our clients from project conception to product launch, acting as a technical extension of the internal team and integrating regulation, quality, operations, and commercial strategy.
Scope of Services in Medicinal Cannabidiol
The pharmaceutical consulting firm ELS Group operates in all stages of the lifecycle of medicinal cannabis projects and products, including, but not limited to:
Strategic and Business Planning
- Developing customized business plans
- Defining operational and strategic models for medicinal cannabis.
- Technical, regulatory, and economic feasibility analysis
Cultivation, Production and Infrastructure
- Crop and production planning
- Land prospecting and qualification
- Engineering, layout and planning of the production unit.
- Consulting services in choosing cultivation and production methods.
Quality, Control and Guarantee
- Implementation of quality management systems
- Quality assurance and control throughout the entire chain.
- Preparation for regulatory audits
- Specialized technical management
Extraction and Production of By-products
- Consulting in extraction processes
- Production of oils and pharmaceutical derivatives
- Evaluation of technologies and production methods
Extraction and Production of By-products
- Consulting in extraction processes
- Production of oils and pharmaceutical derivatives
- Evaluation of technologies and production methods
Regulation and Licensing
- Analysis of the legal status of the project and the product.
- Preparation and submission of regulatory dossiers
- Obtaining authorizations from INFARMED.
- Authorizations for cultivation, manufacturing, import and export.
- EU-GMP certification and support at every stage.
Post-registration and Operation
- Analytical testing and batch release
- Pharmacovigilance management
- Audit management and monitoring
- Administrative authorizations at the municipal level.
The structure behind the ELS Group's Pipeline Management Service for the Pharmaceutical Industry.
The pharmaceutical consulting firm ELS Group has structured its Medicinal Cannabidiol services to address the technical, regulatory, and operational complexities of this highly controlled sector.
Our work is supported by:
Pioneering in Portugal: ELS Group was the first company to conduct a complete registration and regulatory structuring process for Medicinal Cannabis in Portugal, acting from licensing to the operationalization of the regulated model with INFARMED (the Portuguese National Authority of Medicines and Health Products).
Active role in building the regulatory model: beyond project execution, the pharmaceutical consultancy ELS Group actively participated in technical discussions and regulatory contributions, influencing the Portuguese model that now serves as a benchmark for other markets.
Real-world experience “from seed to sale”: a structure prepared to operate in all stages of the cycle: cultivation, production, extraction, quality, EU-GMP certifications, batch release, pharmacovigilance, and access to the international market.
Equipe multidisciplinar especializada: profissionais de assuntos regulatórios, qualidade, engenharia, produção, farmacovigilância e estratégia de negócios, integrados num único modelo de consultoria farmacêutica.
International presence and vision
LATAM–Europe: ability to structure Medicinal Cannabidiol projects with a global vision, respecting the regulatory, commercial and operational particularities of each country.
Integration between regulation, quality and business: the pharmaceutical consulting firm ELS Group works not only to meet legal requirements, but also to create economically viable, scalable and sustainable models.
This structure allows the pharmaceutical consulting firm ELS Group to assume a role that goes beyond one-off advice, acting as an extended regulatory, technical, and strategic structure for the client.
Why Choose ELS Group Pharmaceutical Consulting to Follow the Path to Medicinal Cannabidiol?
Because working with medicinal cannabidiol requires more than just theoretical knowledge. It demands practical experience, regulatory expertise, strategic vision, and real execution capabilities.
ELS Group pharmaceutical consulting is the partner of choice for companies that need to operate safely, predictably, and credibly in one of the most demanding sectors of the healthcare industry.
Frequently asked questions about medicinal cannabidiol for the pharmaceutical industry.
What is ELS Group's Medicinal Cannabidiol consulting service?
It is a specialized pharmaceutical consulting service that supports companies in all stages of medicinal cannabis projects and products, from strategic planning to regulation, production, certification, distribution, and market access.
Does ELS Group handle everything from cultivation to marketing?
Yes. The pharmaceutical consultancy ELS Group operates in an integrated manner from seed to sale, including cultivation, production, extraction, quality, EU-GMP certification, regulation, pharmacovigilance, and distribution strategies.
Does the consulting firm assist in obtaining licenses and certifications?
Yes. We work on the preparation and submission of regulatory dossiers, obtaining ACM and AIM authorizations, cultivation, manufacturing, import and export licenses, as well as EU-GMP certification and preparation for audits.
Does the service include ongoing regulatory support after the product launch?
Yes, it does. The pharmaceutical consulting firm ELS Group offers post-registration support, pharmacovigilance, audit management, batch release, analytical testing, and maintenance of regulatory compliance throughout the product lifecycle.
Does ELS Group participate in regulatory discussions within the sector?
Yes. In addition to project execution, the pharmaceutical consulting firm ELS Group actively participates in technical discussions and public consultations, contributing to the development of regulatory models in emerging markets, such as Brazil.
What is the main differentiating factor of ELS Group's pharmaceutical consulting firm in Medicinal Cannabidiol?
The key difference lies in the combination of real-world practical experience, regulatory expertise, strategic business vision, and integrated execution capabilities, allowing clients to operate with predictability, security, and scalability.
In which countries does the ELS Group operate?
ELS Group operates internationally, with a presence in 11 countries, offering regulatory and quality support in Europe and Latin America.
The company has specialized local teams that work in an integrated manner with the main regulatory authorities in each region, allowing it to align global strategies with the specific regulatory requirements of each market.